FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308367070> ?p ?o ?g. }

• W4308367070 endingPage "1289" @default.
• W4308367070 startingPage "1289" @default.
• W4308367070 abstract "Importance Falls and fractures are frequent and deleterious to the health of older people. Aspirin has been reported to reduce bone fragility and slow bone loss. Objective To determine if daily low-dose aspirin (100 mg) reduces the risk of fractures or serious falls (fall-related hospital presentations) in healthy older men and women. Design, Setting, and Participants This substudy of a double-blind, randomized, placebo-controlled trial studied older adult men and women in 16 major sites across southeastern Australia. The ASPREE-FRACTURE substudy was conducted as part of the Australian component of the ASPREE trial. Between 2010 and 2014 healthy (free of cardiovascular disease, dementia or physical disability), community-dwelling volunteers aged 70 years or older were recruited to participate in the ASPREE trial. Potentially eligible participants were identified by medical practitioners and trial personnel and were then sent a letter of invitation to participate. Interested participants were screened for suitability. Eligible participants with medical practitioner authorization and adherent to a 4-week run-in medication trial were randomized. Data were analyzed from October 17, 2019, to August 31, 2022. Interventions Participants in the intervention group received a daily dose of oral 100 mg enteric-coated (low-dose) aspirin. The control group received a daily identical enteric-coated placebo tablet. Main Outcomes and Measures The primary outcome of ASPREE-FRACTURE was the occurrence of any fracture. The secondary outcome was serious fall resulting in hospital presentation. Results In total, 16 703 people with a median (IQR) age of 74 (72-78) years were recruited, and 9179 (55.0%) were women. There were 8322 intervention participants and 8381 control participants included in the primary and secondary outcome analysis of 2865 fractures and 1688 serious falls over the median follow-up of 4.6 years. While there was no difference in the risk of first fracture between the intervention and control participants (hazard ratio, 0.97; 95% CI, 0.87-1.06; P = .50), aspirin was associated with a higher risk of serious falls (total falls 884 vs 804; incidence rate ratio, 1.17; 95% CI, 1.03-1.33; P = .01). Results remained unchanged in analyses that adjusted for covariates known to influence fracture and fall risk. Conclusions and Relevance In this substudy of a randomized clinical trial, the failure of low-dose aspirin to reduce the risk of fractures while increasing the risk of serious falls adds to evidence that this agent provides little favorable benefit in a healthy, White older adult population. Trial Registration This substudy is registered with the Australian New Zealand Clinical Trials Registry ( ACTRN12615000347561 )." @default.
• W4308367070 created "2022-11-11" @default.
• W4308367070 creator A5025952842 @default.
• W4308367070 creator A5026922332 @default.
• W4308367070 creator A5027073303 @default.
• W4308367070 creator A5040714173 @default.
• W4308367070 creator A5050704054 @default.
• W4308367070 creator A5052343370 @default.
• W4308367070 creator A5054368962 @default.
• W4308367070 creator A5057379795 @default.
• W4308367070 creator A5058775754 @default.
• W4308367070 creator A5061032563 @default.
• W4308367070 creator A5062551704 @default.
• W4308367070 creator A5062620087 @default.
• W4308367070 creator A5064816095 @default.
• W4308367070 creator A5068463698 @default.
• W4308367070 creator A5070424397 @default.
• W4308367070 creator A5083020354 @default.
• W4308367070 creator A5086281548 @default.
• W4308367070 date "2022-12-01" @default.
• W4308367070 modified "2023-10-18" @default.
• W4308367070 title "Daily Low-Dose Aspirin and Risk of Serious Falls and Fractures in Healthy Older People" @default.
• W4308367070 cites W1533850659 @default.
• W4308367070 cites W1774931820 @default.
• W4308367070 cites W1897540949 @default.
• W4308367070 cites W1965685191 @default.
• W4308367070 cites W2067355012 @default.
• W4308367070 cites W2070770519 @default.
• W4308367070 cites W2078978685 @default.
• W4308367070 cites W2109533456 @default.
• W4308367070 cites W2125658386 @default.
• W4308367070 cites W2144070181 @default.
• W4308367070 cites W2164059021 @default.
• W4308367070 cites W2329387762 @default.
• W4308367070 cites W2570796465 @default.
• W4308367070 cites W2751792491 @default.
• W4308367070 cites W2805993147 @default.
• W4308367070 cites W2889884522 @default.
• W4308367070 cites W2891412296 @default.
• W4308367070 cites W2892288854 @default.
• W4308367070 cites W3000146346 @default.
• W4308367070 cites W3007474884 @default.
• W4308367070 cites W3010766927 @default.
• W4308367070 cites W3013555770 @default.
• W4308367070 cites W4213228061 @default.
• W4308367070 cites W4244074116 @default.
• W4308367070 cites W4251072842 @default.
• W4308367070 doi "https://doi.org/10.1001/jamainternmed.2022.5028" @default.
• W4308367070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36342703" @default.
• W4308367070 hasPublicationYear "2022" @default.
• W4308367070 type Work @default.
• W4308367070 citedByCount "3" @default.
• W4308367070 countsByYear W43083670702023 @default.
• W4308367070 crossrefType "journal-article" @default.
• W4308367070 hasAuthorship W4308367070A5025952842 @default.
• W4308367070 hasAuthorship W4308367070A5026922332 @default.
• W4308367070 hasAuthorship W4308367070A5027073303 @default.
• W4308367070 hasAuthorship W4308367070A5040714173 @default.
• W4308367070 hasAuthorship W4308367070A5050704054 @default.
• W4308367070 hasAuthorship W4308367070A5052343370 @default.
• W4308367070 hasAuthorship W4308367070A5054368962 @default.
• W4308367070 hasAuthorship W4308367070A5057379795 @default.
• W4308367070 hasAuthorship W4308367070A5058775754 @default.
• W4308367070 hasAuthorship W4308367070A5061032563 @default.
• W4308367070 hasAuthorship W4308367070A5062551704 @default.
• W4308367070 hasAuthorship W4308367070A5062620087 @default.
• W4308367070 hasAuthorship W4308367070A5064816095 @default.
• W4308367070 hasAuthorship W4308367070A5068463698 @default.
• W4308367070 hasAuthorship W4308367070A5070424397 @default.
• W4308367070 hasAuthorship W4308367070A5083020354 @default.
• W4308367070 hasAuthorship W4308367070A5086281548 @default.
• W4308367070 hasConcept C118552586 @default.
• W4308367070 hasConcept C126322002 @default.
• W4308367070 hasConcept C142724271 @default.
• W4308367070 hasConcept C168563851 @default.
• W4308367070 hasConcept C1862650 @default.
• W4308367070 hasConcept C204787440 @default.
• W4308367070 hasConcept C27081682 @default.
• W4308367070 hasConcept C27415008 @default.
• W4308367070 hasConcept C2776541429 @default.
• W4308367070 hasConcept C2777628954 @default.
• W4308367070 hasConcept C2778885795 @default.
• W4308367070 hasConcept C2779134260 @default.
• W4308367070 hasConcept C2779483572 @default.
• W4308367070 hasConcept C3020151743 @default.
• W4308367070 hasConcept C54183767 @default.
• W4308367070 hasConcept C71924100 @default.
• W4308367070 hasConceptScore W4308367070C118552586 @default.
• W4308367070 hasConceptScore W4308367070C126322002 @default.
• W4308367070 hasConceptScore W4308367070C142724271 @default.
• W4308367070 hasConceptScore W4308367070C168563851 @default.
• W4308367070 hasConceptScore W4308367070C1862650 @default.
• W4308367070 hasConceptScore W4308367070C204787440 @default.
• W4308367070 hasConceptScore W4308367070C27081682 @default.
• W4308367070 hasConceptScore W4308367070C27415008 @default.
• W4308367070 hasConceptScore W4308367070C2776541429 @default.
• W4308367070 hasConceptScore W4308367070C2777628954 @default.
• W4308367070 hasConceptScore W4308367070C2778885795 @default.

• next